Immunic Ag
Clinical trials sponsored by Immunic Ag, explained in plain language.
-
New MS pill aims to slash relapses in major trial
Disease control OngoingThis phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingThis Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC